À proposConditionsConfidentialitéContact
 
Actualisation
A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

Annenberg Center for Health Sciences
Date de sortie : 2022-06-09
© Annenberg Center for Health Sciences
A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy - QR Code
Libre0%
4 épisodes
Audio
Écouter sur Apple Podcasts
Libre0%
4 épisodes
Audio
Écouter sur Apple Podcasts
Date de sortie : 2022-06-09
© Annenberg Center for Health Sciences
L’épisode le plus récent
Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies

Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies

Durée : 8:02
Lecture
Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies.
Id. d’épisode : 1000565790983
GUID : 6e20c492-4ea1-48ef-8b3a-b99b964743d9
Date de publication : 9/6/2022 à 17:28:29

Description

In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.

Adresse du flux

https://anchor.fm/s/9dbd9334/podcast/rss

Apple Podcasts : Avis des utilisateurs

Pas d'entrée